Pat Gibbs Told to 'Put Her House in Order' in 1996 - Celebrates Her 79th Birthday This Year FRANKLIN, Mass., Sept. 9 /PRNewswire-FirstCall/ -- PLC Systems Inc. (AMEX: PLC), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that Pat Gibbs, a cardiac patient who had been told "nothing could be done for her," in 1996 has now celebrated her 12th year of angina-free living, following the implementation of PLC's therapy. Ms. Gibbs was treated with PLC's patented CO2 Transmyocardial Revascularization (TMR) in August 1996 at the Washington Hospital Center, Washington, D.C. Prior to her treatment, she had received a variety of therapies including numerous medications, several interventions, and two coronary bypass surgeries. Despite this, she continued to suffer with angina, which severely limited her quality of life. "Prior to the TMR procedure, I was living on nitroglycerine tablets," said Ms. Gibbs. "Each morning, even the simplest effort forced me to take another tablet in order to take my next step. I was told that I needed a heart transplant, but was rejected because of my age. "Although I was suffering from non-stop chest pain, I was told to go home and to pray. The doctors said there was nothing more they could do." Ms. Gibbs lives in northern Alabama and continues to lead an active, healthy life. She has traveled around the country since her procedure, and enjoys volunteering in her community at the local Art Association and gardening. More than 15,000 other TMR patients have been treated successfully with PLC's technology. Women and Heart Disease According to the American Heart Association, heart disease is the leading killer of women in the United States. About 460,000 women die of cardiovascular disease annually, more than the total number of cardiovascular disease-related deaths in men or the next five causes of death combined. A study in the March 22/29, 2006 issue of the Journal of the American Medical Association found that women have as high an incidence of stable angina as men and that this is associated with an increased risk of coronary death in women. Angina is a sign of increased risk for heart attack, cardiac arrest and sudden cardiac death. More information on risk factors and programs that help to build awareness of this issue are available at http://www.goredforwomen.org/ and http://www.americanheart.org/ . Transmyocardial Revascularization Transmyocardial Revascularization, or TMR, is a surgical revascularization procedure that requires visualization of the heart. TMR may be performed either through a minimally invasive or an open surgical approach that is determined by the surgeon. During the CO2 TMR procedure, a cardiac surgeon utilizes a CO2 laser to create approximately 20 to 40 channels through the wall of the heart (myocardium) to promote increased blood flow. In clinical studies, CO2 TMR has demonstrated a reduction in angina and an improvement in quality of life. It is believed the creation of TMR channels promotes angiogenesis, the development and formation of new blood vessels. The CO2 Heart Laser(TM) 2 system is manufactured by PLC Medical Systems, Inc., and distributed in the United States by Novadaq Corporation, a wholly-owned U.S. subsidiary of Novadaq Technologies, Inc. (TSX: NDQ). Studies are underway to investigate the potential benefits of combining CO2 TMR with stem cell therapy. The combined therapy may lead to improved cardiac function in heart failure patients. About PLC Systems Inc. PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. PLC's newest product, RenalGuard(TM), is approved for sale in the EU as a general fluid balancing device. The RenalGuard System(TM) consists of a unique, proprietary, closed loop, software-controlled console and accompanying single-use sets that can be used by physicians and nurses to balance patient fluid levels during a variety of medical procedures. The RenalGuard System, with its matched fluid replacement capability, is intended to minimize the risk of over- or under-hydration during medical procedures where creating and maintaining high urine outputs is deemed beneficial to patients. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. CO2 TMR offers a treatment option for angina patients who suffer from severe coronary artery disease. The CO2 Heart Laser is the world's first TMR angina relief device cleared for commercial distribution by both the U.S. Food and Drug Administration and Japanese Ministry of Health, Labor and Welfare, and to obtain a CE Mark for European distribution. Additional company information can be found at http://www.plcmed.com/ . This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to raise sufficient funds in the future to implement our business plan and/or commence our planned U.S. clinical trial for RenalGuard, the current CCM clinical trial and the planned future U.S. clinical trial for RenalGuard as a safe and effective CIN prevention device may not be completed in a timely fashion if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2007, and our other SEC reports. PLC Systems, PLC Medical Systems, PLC and CO2 Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc. Contact: Mary T. Conway Conway Communications 617-244-9682 DATASOURCE: PLC Systems Inc. CONTACT: Mary T. Conway of Conway Communications, +1-617-244-9682, , for PLC Systems Inc. Web site: http://www.plcmed.com/ http://www.americanheart.org/ http://www.goredforwomen.org/

Copyright